ScreenerHero

CVM CEL-SCI Corporation

AMEX · US · Healthcare · Biotechnology · cel-sci.com
2.130USD-22.26%Mkt Cap: 37.46M $P/E: —

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap37.46M USD
Enterprise Value49.56M USD
Revenue (TTM)—
Gross Profit-14.80M USD
Net Income (TTM)-25.41M USD
Revenue/Share—
Last Price2.130 USD
Fiscal Year EndSep 2025
MR QuarterJun 2026
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.43
PEG1.12
EV/EBITDA-2.45
EV/Revenue—
P/S—
P/B4.40
EPS (TTM)-1.69
EPS (Forward)-6.38
52W Range
0.890012% of range10.83
52W High10.83 USD
52W Low0.8900 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-159.25%
ROA-90.25%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-17.12M USD
CapEx (TTM)38.11K USD
FCF Margin—
FCF Yield-23.80%
Net Debt1.36M USD
Net Debt/EBITDA-0.07
Balance Sheet
Debt/Equity0.59
Current Ratio1.48
Quick Ratio1.29
Book Value/Sh0.62 USD
Cash/Share0.37 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div DateAug 28, 1996
Pay DateJun 15, 2017
Splits
Last Split1:30
Split DateMay 20, 2025
Analyst Consensus
Rating—
Target (Mean)12.50 USD
Upside (mean)+486.9%
Target Range10.00 USD – 15.00 USD
10.00+486.9% to mean15.00
# Analysts2
Ownership
Shares Out.17.59M
Float16.92M
Insiders3.71%
Institutions14.63%
Short Interest
Short Ratio4.7d
Short % Float3.63%
Short % Out.3.52%
Shares Short619.26K
Short (prev mo.)714.47K
Technical
SMA 501.610 (+32.3%)
SMA 2002.835 (-24.9%)
Beta0.59
S&P 52W Chg16.45%
Avg Vol (30d)240.24K
Avg Vol (10d)339.99K
Technical Indicators
RSI (14)58.0
MACD0.2368
MACD Signal0.1710
MACD Hist.+0.0658
BB Upper2.526 USD
BB Middle1.826 USD
BB Lower1.126 USD
BB Width76.71%
ATR (14)0.2387 USD
Vol Ratio (20d)2.84x